Interpace Diagnostics Group, Inc. (IDXG) financial statements (2021 and earlier)

Company profile

Business Address MORRIS CORPORATE CENTER 1,
PARSIPPANY, NJ 07054
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 615182346
Cash and cash equivalents 615182346
Short-term investments    000
Receivables 932 (0)(0)
Prepaid expense    0  
Deferred costs     02
Disposal group, including discontinued operation    51 
Prepaid expense and other current assets7
Other current assets 21137 
Other undisclosed current assets   03138
Total current assets: 18204194563
Noncurrent Assets
Property, plant and equipment 111133
Long-term investments and receivables     32
Long-term investments     32
Intangible assets, net (including goodwill) 303336431103
Goodwill     163
Intangible assets, net (excluding goodwill) 3033364394 
Disposal group, including discontinued operation, noncurrent assets   001
Other noncurrent assets 00035 
Prepaid expense and other noncurrent assets1
Assets of disposal group, including discontinued operation0
Other undisclosed noncurrent assets   (0) (51)(2)
Total noncurrent assets: 31343849716
TOTAL ASSETS: 4854426811669
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 8712102822
Accounts payable 102242
Accrued liabilities 55661510
Employee-related liabilities 1142810
Interest and dividends payable     0 
Settlement liabilities     1
Debt    1  
Restructuring reserve     1
Liability for uncertainty in income taxes     11
Disposal group, including discontinued operation 1141230
Self insurance reserve     01
Business combination, contingent consideration, liability     1
Deferred revenue and credits   79
Deferred tax liabilities    (1) 
Other undisclosed current liabilities     (5)(2)
Total current liabilities: 8816233431
Noncurrent Liabilities
Long-term debt and lease obligation   8 27 
Long-term debt, excluding current maturities   8 27 
Liabilities, other than long-term debt, including: 4446356
Deferred revenue and credits  001
Deferred tax liabilities, net    3 
Liability for uncertainty in income taxes 444333
Regulatory liability   033 
Restructuring reserve     01
Disposal group, including discontinued operation, liabilities     01
Other liabilities 00 000
Business combination, contingent consideration, liability     26
Other undisclosed liabilities, other than long-term debt  0    
Other undisclosed noncurrent liabilities 017 (53)(1)
Total noncurrent liabilities: 4619695
Other undisclosed liabilities 3  2553 
Total liabilities: 161435559637
Stockholders' equity
Stockholders' equity attributable to parent, including: 33407132032
Common stock 000   
Treasury stock, value (2)(2)(2)(8)(14)(14)
Additional paid in capital 176173128133134130
Accumulated other comprehensive income    000
Accumulated deficit (141)(132)(120)(111)(100)(84)
Other undisclosed stockholders' equity attributable to parent    000
Total stockholders' equity: 33407132032
TOTAL LIABILITIES AND EQUITY: 4854426811669

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues 2216139120151
Revenue, net16139120151
Cost of revenue (10)(7)(7)(7)(129)(157)
Cost of goods and services sold (10)   (129)(157)
Other undisclosed gross profit     2731
Gross profit: 129631924
Operating expenses (24)(15)(13)(43)(32)(29)
Operating loss: (12)(6)(6)(40)(13)(4)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
 0(2)0(0)(0)(0)
Interest and debt expense (0)(5)(2)(0)(1) 
Loss from continuing operations before equity method investments, income taxes: (12)(13)(9)(41)(14)(4)
Other undisclosed loss from continuing operations before income taxes    (3)  
Loss from continuing operations before income taxes: (12)(13)(9)(44)(14)(4)
Income tax expense (benefit) (0)00135(0)
Loss from continuing operations: (12)(13)(8)(31)(9)(5)
Income (loss) from discontinued operations 01020(7)(0)
Net loss available to common stockholders, diluted: (12)(12)(8)(11)(16)(5)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (12)(12)(8)(11)(16)(5)
Comprehensive loss: (12)(12)(8)(11)(16)(5)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent    (0) 0
Comprehensive loss, net of tax, attributable to parent: (12)(12)(8)(11)(16)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: